Exploring Real-World HER2-Low Data in Early-Stage Triple-Negative Breast Cancer: Insights and Implications.

Breast Cancer (Dove Med Press) · 2023 · PMC10178312 · PMID 37188066

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

However, Residual Cancer Burden (RCB) of 0/1 showed a trend toward higher frequency in HER2 IHC 2+ (47.1%) in comparison to HER2 IHC 1+ (31.5%) and HER2 IHC 0 (25%), as demonstrated in Table 1 .

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.